

Risk-Reduction Mastectomy

Last Review Date: May 12, 2017

Number: MG.MM.SU.11f

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

<p>Risk-reduction mastectomy (aka prophylactic mastectomy)</p>	<p>Surgical removal of the breast to prevent the occurrence or recurrence of cancer.</p>
<p>Hereditary breast or ovarian cancer (HBOC) syndrome</p>	<p>Testing criteria include any of the following:¹</p> <ul style="list-style-type: none"> ✓ Individual from family of known deleterious BRCA1/BRCA2 mutation or other cancer susceptibility gene ✓ Personal history of breast cancer and ≥ 1 of the following: <ul style="list-style-type: none"> ▪ Diagnosed ≤ 45 y² ▪ Diagnosed ≤ age 50 y with <ul style="list-style-type: none"> • An additional breast cancer primary³ • ≥ 1 close blood relative with breast cancer at any age • An unknown or limited family history ▪ Diagnosed ≤ 60 y with a: <ul style="list-style-type: none"> • Triple negative breast cancer ▪ Diagnosed at any age with <ul style="list-style-type: none"> • ≥ 1 close blood relative with breast cancer diagnosed ≤ 50 y • ≥ 2 close blood relatives with breast cancer at any age • ≥ 1 close blood relative with invasive ovarian cancer • ≥ 2 close blood relatives with pancreatic cancer and/or prostate cancer (Gleason score > 7) at any age • A Close male blood relative with breast cancer • For an individual of ethnicity associated with higher mutation frequency

¹ National Comprehensive Cancer Network (NCCN) criteria suggestive of hereditary breast or ovarian cancer syndrome that warrant further professional evaluation. When investigating family histories for HBOC, all close relatives on the same side of the family should be included. Close relatives include first-, second- and third-degree relatives.

² May consider age range between 40 and 50 if clinical situation warrants.

³ Two breast primaries include bilateral disease or cases where there are two or more clearly separate, ipsilateral, primary tumor diseases.

<p>(e.g., Ashkenazi Jewish) no additional family history may be required</p> <ul style="list-style-type: none"> ✓ Personal history of ovarian cancer ✓ Personal history of male breast ✓ Close blood relative meeting any of the above criteria.

Guideline

Members at high risk of developing breast cancer are eligible for risk-reduction mastectomy and breast reconstruction (augmentation mammoplasty),⁴ inclusive of all lines of business,⁵ when the below criteria are met.

(Members with positive BRCA1, BRCA2, PTEN, P53 or CDHI findings should be referred for genetic counseling)

<p>Bilateral risk-reduction mastectomy</p>	<p>Any:</p> <ol style="list-style-type: none"> 1. Family history of breast cancer in a 1st-degree relative, especially a mother or sister, who is premenopausal and has had bilateral breast cancer (family cancer syndrome). 2. Known mutation of BRCA1, BRCA2, PTEN, P53 or CDHI breast cancer susceptibility genes. 3. Member received therapeutic thoracic radiation at < 30 years of an age.
<p>Unilateral risk-reduction mastectomy for members with cancer in the contralateral breast</p>	<p>Any:</p> <ol style="list-style-type: none"> 1. Diffuse microcalcifications in the remaining breast, especially when ductal carcinoma in situ has been diagnosed in the contralateral breast. 2. Lobular carcinoma in situ in the remaining breast. (This diagnosis is a marker of risk for the development of invasive cancer and carries special significance when the previously treated breast had either invasive or in situ lobular disease) 3. Development of either invasive lobular or ductal carcinoma in a member who has elected surveillance for lobular carcinoma in situ. (This member is at significant risk; 8 – 10 times normal) for the development of cancer in the intact breast. 4. Premenopausal at development of 1st breast cancer. 5. Known mutation of BRCA1 or BRCA2 breast cancer susceptibility genes. 6. Member received therapeutic thoracic radiation at < 30 years of an age.
<p>Risk-reduction mammoplasty for members with no prior history of breast cancer</p>	<p>Any:</p> <ol style="list-style-type: none"> 1. Atypical ductal hyperplasia on multiple bilateral biopsies. 2. History of ≥ 2 premenopausal 1st-degree relatives with breast cancer 3. LCIS or DCIS on multiple bilateral breast biopsies. 4. Known mutation of BRCA1 or BRCA2 breast cancer susceptibility genes.

Limitations/Exclusions

A Medical Director will review any request for surgery that does not meet the guideline.

Revision History

5/12/2017 — corrected “≤” symbol error within section of personal history of breast cancer; subsection of diagnosed ≤ age 50 y; subsection of ≤ 1 close blood relative with breast cancer at any age (≤ 1 changed to ≥ 1)

⁴ As per, *inter alia*, the federal Women’s Health and Cancer Rights Act of 1998, augmentation mammoplasty is covered for restoration and achievement of symmetry incidental to mastectomy. The Plan does not provide benefit coverage for cosmetic indications other than the indication listed above. Reconstruction shall include augmentation of the breast on which the mastectomy was performed and, as applicable, surgery and reconstruction on the unaffected breast to produce a symmetrical appearance. Coverage for reconstructive surgery and prosthetic devices shall be subject to the deductible and coinsurance conditions applied to the mastectomy and all other terms and conditions applicable to other benefits.

⁵ Coverage is provided for subsequent breast reconstruction for any woman who undergoes a mastectomy for a medical reason.

Applicable Procedure Codes

19303	Mastectomy, simple, complete
19304	Mastectomy, subcutaneous

Applicable ICD-10 Diagnosis Codes

C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.121	Malignant neoplasm of central portion of right male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast

C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C79.81	Secondary malignant neoplasm of breast
D05.00	Lobular carcinoma in situ of unspecified breast
D05.01	Lobular carcinoma in situ of right breast
D05.02	Lobular carcinoma in situ of left breast
D05.10	Intraductal carcinoma in situ of unspecified breast
D05.11	Intraductal carcinoma in situ of right breast
D05.12	Intraductal carcinoma in situ of left breast
D05.80	Other specified type of carcinoma in situ of unspecified breast
D05.81	Other specified type of carcinoma in situ of right breast
D05.82	Other specified type of carcinoma in situ of left breast
D05.90	Unspecified type of carcinoma in situ of unspecified breast
D05.91	Unspecified type of carcinoma in situ of right breast
D05.92	Unspecified type of carcinoma in situ of left breast
Z15.01	Genetic susceptibility to malignant neoplasm of breast
Z80.3	Family history of malignant neoplasm of breast
Z85.3	Personal history of malignant neoplasm of breast

References

Lopez MJ, Porter KA. Current role of prophylactic mastectomy. *Surg Clin North Am.* 1996;76:231-242.

NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. V2. 2017.

http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 18, 2017.

NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V2.2017.

http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed May 18, 2017.

Specialty-matched clinical peer review.